Moneygram CEO Talks...
Health Care: Drugs
Redhill Biopharma Ltd (RDHL: NASDAQ)
$10.64 -0.46 | -4.14%
05/22/13 - 03:43 PM ET
Portfolios with RDHL
- Portfolio NameUser Type
Latest RDHL Headlines from TheStreet
- RedHill Biopharma Reports Financial Results For The First Quarter Of 2013 05.02.13 | 11:05 am
- RedHill Biopharma Submits New Drug Application To U.S. FDA For RHB-103 Anti-Migraine Oral Thin Film 03.27.13 | 06:03 am
- RedHill Biopharma Receives Positive Feedback From A Scientific Advice Meeting In Europe Regarding RHB-101 (Hypertension) Marketing Application Plan 03.19.13 | 05:03 am
- RedHill Biopharma To Present At The 25th Annual ROTH Conference 03.06.13 | 09:03 am
- RedHill Biopharma Provides Update On Development Progress And Planned NDA Submission For RHB-102 (Oncology Support Anti-Emetic) 02.25.13 | 08:02 am
- RedHill Biopharma Reports 2012 Fourth Quarter And Year-End Results 02.19.13 | 11:02 am
- RedHill Biopharma Announces Notice Of Allowance From The United States Patent And Trademark Office For Its Cardio Drug RHB-101 02.19.13 | 09:02 am
- RedHill Biopharma Announces Date Of 2012 Financial Results And Corporate Update Conference Call 02.14.13 | 09:02 am
Press Releases for RDHL
- Bioassociate Announces Valuation Report On RedHill Biopharma, Ltd. - PR Newswire 04.03.13 | 09:04 am
Partner Headlines for RDHL
